General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria
Germany
Contact person: Jean-Paul Kress, Chief Executive Officer
Company main phone: +49 (89) 899270
Website: https://www.morphosys.com
Year founded: | 1992
|
Source of foundation: | Independent foundation |
Name of foundation source: | Founded by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun |
No. of employees: |
Worldwide: 524 |
Corporate description / mission:
MorphoSys is a global biopharmaceutical company with a high-level focus on the development of innovative medicines, primarily in the oncology sector. The company's main offerings include the research, development, and delivery of therapies aimed at treating difficult-to-treat and debilitating types of cancer. MorphoSys primarily serves the healthcare and pharmaceutical industries.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Antibodies
- Immunotherapy
- Small molecules
|
Primary therapeutic areas: |
- Cardiovascular / cardiology
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Endocrine, nutritional and metabolic diseases / endocrinology
- Musculoskeletal system and connective tissue / Orthopedics
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
- Skin and subcutaneous tissue / dermatology
|
Business model: |
- Manufacturer
- Out-licensing
- R&D
- Supplier / Distributor
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
- Physicians / doctors
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Phase I: | 2 | |
Phase II: | 5 | |
Phase III: | 6 | |
On the market: | 1 | |
Description of products:
Tafasitamab
Pelabresib, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2023
Revenues: | USD 257.82M | |
R&D expenses: | USD 306.87M | |
Cash: | USD 171.50M | |
Total liabilities: | USD 2'139.40M | |
No. of shares: | 37'716'400 | |
Market cap. / valuation: | USD 2'724.22M | |
Collaborations & Clients
Partnering strategy / collaborations:
Novartis
I-Mab
GSK
pfizer
Ultragenyx and Mereo Biopharma etc